ARTL · Artelo Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $773.0K | - | $1.27M | $1.87M | $1.38M | - | $325.0K | $1.69M | $1.51M | - |
| SG&A | $1.92M | - | $1.81M | $1.28M | $995.0K | - | $870.0K | $827.0K | $1.08M | - |
| Total Operating Expenses | $2.69M | - | $3.09M | $3.15M | $2.38M | - | $1.20M | $2.51M | $2.59M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($2.69M) | - | ($3.09M) | ($3.15M) | ($2.38M) | - | ($1.20M) | ($2.51M) | ($2.59M) | - |
| Interest Expense | $0 | - | $111.0K | $0 | - | - | - | - | - | - |
| Income Tax | - | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($2.96M) | - | ($3.12M) | ($3.22M) | ($2.37M) | - | ($1.13M) | ($2.43M) | ($2.48M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($4.00) | - | ($3.97) | ($5.61) | ($0.78) | - | ($0.83) | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.27M | $600.0K | $1.72M | $2.07M | $746.0K | $2.34M | $4.36M | $881.0K | $1.20M | $2.81M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $10.42M | $695.0K | $1.83M | $2.23M | $1.38M | $2.56M | $4.99M | $6.17M | $8.19M | $10.98M |
| Total Assets | $12.52M | $2.80M | $4.27M | $4.36M | $3.52M | $4.70M | $7.14M | $8.33M | $10.35M | $13.04M |
| Current Liabilities | $5.83M | $4.04M | $4.86M | $5.71M | $2.80M | $1.77M | $697.0K | $940.0K | $721.0K | $1.29M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $5.85M | $4.07M | $4.90M | $5.76M | $2.86M | $1.84M | $775.0K | $1.03M | $817.0K | $1.29M |
| Stockholders' Equity | $6.67M | ($1.27M) | ($633.0K) | ($1.41M) | $652.0K | $2.86M | $6.36M | $7.30M | $9.54M | $11.75M |
| Retained Earnings | ($65.97M) | ($63.02M) | ($58.85M) | ($55.73M) | ($52.51M) | ($50.14M) | ($46.36M) | ($45.23M) | ($42.79M) | ($40.31M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.19M) | - | - | - | ($1.60M) | - | - | - | ($2.94M) | - |
| Investing Cash Flow | - | - | - | - | $0 | - | - | - | $1.27M | - |
| Financing Cash Flow | $10.86M | - | - | - | $0 | - | - | - | $55.0K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -23.6% | - | -73.1% | -73.9% | -67.5% | - | -15.9% | -29.2% | -24.0% | - |
| Return on equity | -44.3% | - | 492.9% | 229.1% | -363.8% | - | -17.8% | -33.3% | -26.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.79 | 0.17 | 0.38 | 0.39 | 0.49 | 1.44 | 7.15 | 6.56 | 11.36 | 8.51 |
| Quick ratio | 1.79 | 0.17 | 0.38 | 0.39 | 0.49 | 1.44 | 7.15 | 6.56 | 11.36 | 8.51 |
| Cash ratio | 1.76 | 0.15 | 0.35 | 0.36 | 0.27 | 1.32 | 6.25 | 0.94 | 1.66 | 2.18 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -27.8x | - | - | - | - | - | - | - |
| Equity multiplier | 1.88 | -2.20 | -6.74 | -3.10 | 5.39 | 1.64 | 1.12 | 1.14 | 1.09 | 1.11 |
| Liabilities / Assets | 0.47 | 1.45 | 1.15 | 1.32 | 0.81 | 0.39 | 0.11 | 0.12 | 0.08 | 0.10 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -13.0% | - | -158.5% | -25.4% | 8.1% | - | 54.3% | -40.8% | -13.0% | - |
| Net income growth (YoY) | -24.7% | - | -175.6% | -32.4% | 4.5% | - | 53.8% | -52.2% | -14.5% | - |
| EPS growth (YoY) | -412.8% | - | -378.3% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 923.3% | - | - | - | -93.2% | -75.7% | -56.4% | -55.1% | -45.9% | -39.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ARTELO BIOSCIENCES against the 5 most active filers in the same SIC group.